Mounjaro on X: who shapes the conversation

When researchers at Princess Nourah University in Saudi Arabia mapped the Mounjaro conversation on X (formerly Twitter) earlier this year, they found a pattern that will surprise no one who follows health social media: the most influential voices were not doctors^[1]. They were patients sharing personal experiences and public figures with large followings.

The study, published in the Saudi Pharmaceutical Journal in July 2026, collected 5,566 tweets from 5,641 users between January and February 2025 and ran them through social network analysis using NodeXL^[1]. The method measures two things: betweenness centrality (which accounts sit on the most information pathways) and in-degree centrality (which accounts receive the most mentions). By both measures, the top-ranked users in the Mounjaro network were predominantly non-medical.

What the network looked like

The 5,641 accounts in the dataset did not form a single uniform cloud. Cluster analysis revealed several distinct conversation groups: one focused on weight loss outcomes, one on comparisons with similar medicines (including semaglutide, sold as Ozempic and Wegovy), one on pharmaceutical branding, and one on tirzepatide as a diabetes treatment^[1]. The weight-loss cluster was the largest, reflecting the off-label uptake that has characterised tirzepatide since the SURMOUNT trial programme began generating results.

Sentiment ran mostly positive: 62.6% of tweets expressed favourable attitudes toward Mounjaro^[1]. That figure aligns broadly with a separate longitudinal analysis of 859,751 semaglutide posts on X from July 2021 to April 2024, which found an overall negative mean score of only -0.24, with organizational accounts (mean -0.04) expressing far less negativity than individual users (mean -0.28)^[2]. The semaglutide study found sentiment declining over time, particularly in late 2022, when regulatory announcements on adverse effects circulated widely. The Mounjaro data does not yet have that longitudinal dimension.

Why this matters for health information

Social network analysis of drug conversations is not new. An earlier Twitter study on antiobesity medications published in the Journal of Medical Internet Research examined 2,045 tweets from September to October 2019 and found liraglutide and semaglutide dominated discussion, with treatment efficacy generating the most conversation volume and semaglutide-related content attracting the highest engagement^[3]. Across that and the newer work, the consistent finding is that drug conversation on social media is largely patient-driven and positivity-skewed.

The clinical concern is not that patients talk to each other online. The concern is that network centrality on a platform like X correlates with reach, not expertise. A patient who lost 20 kg on tirzepatide and posts about it daily can accumulate more followers and mentions than an endocrinologist who posts careful summaries of trial data. The AlHazmi study found this dynamic in place for Mounjaro: the accounts with the most network influence were not the most medically informed.

What the literature actually says about tirzepatide

For contrast, the clinical trial record for tirzepatide is substantial and largely favourable. In SURMOUNT-1, tirzepatide 15 mg produced a mean 20.9% body-weight reduction at 72 weeks in adults with obesity or overweight without diabetes^[4]. Those are the numbers that social media often cites, though typically without the full trial context: prescription-only access, a structured dose titration from 2.5 mg to 15 mg over months, gastrointestinal side effects in roughly a third of participants, and the weight-regain pattern documented in SURMOUNT-4 after discontinuation.

Regulatory status also tends to get lost in social amplification. Tirzepatide is prescription-only in every major market. In the United States it is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. In the EU, the EMA authorised Mounjaro for both indications under a single brand. The FDA has issued warning letters to compounding pharmacies selling unapproved tirzepatide preparations. None of that appears prominently in the positive-experience posts that drive network centrality on X.

The same dynamic appears for other agents in the class. Semaglutide has been sold as Ozempic (for type 2 diabetes) and Wegovy (for obesity), and the off-label weight-loss use of Ozempic spread largely through social media before Wegovy was widely available. The Mounjaro conversation studied by AlHazmi is a later iteration of a pattern already visible in the semaglutide data from 2019 onwards.

What to take from this

The AlHazmi finding is a useful calibration tool, not a reason to avoid social media. Patients comparing notes on injection technique, titration schedules, or side-effect management can be genuinely useful to one another. The limits kick in when social media replaces the prescribing consultation rather than supplementing it.

For readers considering tirzepatide, the better reference point is the published trial literature and your prescriber, not the account with the most followers. The gap between a viral weight-loss post and the full pharmacological picture is exactly what drug information research keeps measuring, and the Mounjaro network study adds another data point to an established pattern.

This article is for educational and informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making any treatment decision.